A new test has been developed that reduces the time it takes to diagnose types of brain tumours from weeks to just hours, researchers say. Surgeons have described the "ultra-rapid" method of genetic testing as a "game changer" and say it could improve care and treatment for thousands of patients. The method has been developed by scientists at the University of Nottingham in partnership with clinicians at Nottingham University Hospitals NHS Trust (NUH). The research has attracted interest from across the UK, with other NHS hospitals setting up their own testing alongside their existing regimes to gather more evidence about its effectiveness. A study published on Wednesday reveals the method has already been used in 50 operations at NUH and has had a 100% success rate in diagnosing the exact type of tumour. There are currently more than 100 identified types of brain tumour, and clinicians need to identify which kind a patient has to determine the most effective way to treat them. Traditionally, samples of tumours are extracted during surgery to be taken away, tested, and examined under a microscope in a pathology lab. While the process is mostly accurate, it can take up to eight weeks to definitively diagnose the type of tumour. Stuart Smith, NUH consultant neurosurgeon, said: "Sometimes once we do get the full diagnosis back from the laboratory, we realise it's a type of tumour that would really benefit from what we call more radical surgery to remove every last piece of tumour, if that hasn't been done at the first operation. "Sadly, sometimes that does mean a patient has to undergo a second, or sometimes even a third operation, to ensure that all the tumour that can be surgically removed has been." However, the new technique has seen results returned in as little as 90 minutes, and Mr Smith said it was possible to get a diagnosis while a patient was still in the operating theatre for their original procedure. It means surgeons would be able to perform more radical surgery, if needed, at the time. Mr Smith also said faster classification could allow patients to get radiation treatment or chemotherapy, more quickly, and that the quicker diagnoses often reduced the anxiety patients felt while waiting for test results. "It is a game changer," he added. Prof Matt Loose, a biologist at the University of Nottingham's School of Life Sciences, developed the new method using software dubbed ROBIN. Using nanopore genetic sequencing, he said, scientists are able to choose which parts of the DNA to look at in detail, delivering a faster result. He said: "Sadly most brain tumours are incredibly aggressive and waiting six to eight weeks, or however long, for every subsequent test may be too long for that patient. "Now we can get the results within hours and that can happen within an operation while a patient is still in theatre." Gemma's daughter Nancy was diagnosed with a brain tumour aged just one in 2023. The now two-year-old had two brain surgeries, then high-dose chemotherapy treatment to prevent the cancer from coming back. Gemma, from Castle Donington in Leicestershire, said: "From Nancy's first surgery to finding out what that tumour was, it was two weeks, and that was two weeks of pure hell and anxiety. "But to have it done that quick it could have saved her that extra brain surgery." Nancy is now in remission and has becomethe face of a national TV advert for Young Lives vs Cancer, a charity that supported the family during her treatment. Charles Trigg, who lives near Market Harborough in Leicestershire, was diagnosed with a stage four aggressive glioblastoma tumour in April. He was told his tumour was the size of a golf ball. The 45-year-old, who has been treated by Mr Smith, said: "To have knowledge is power and it could be the worst knowledge you have, but it gives you certainty, and having that certainty actually makes life a hell of a lot easier. "The fact they've been able to get back data very quickly that allows an extensive team of people to conduct detailed reviews feels like an amazing blend of science and medicine. "The pace is phenomenal, and it gives you that certainty and clarity, regardless of whether you like the information, I can't change the information, but what I can do, is take the information I've been given early - and absorb it, feel it and start to plan for the next stage." Brain tumours are the biggest cancer killer of children and adults under 40, according to The Brain Tumour Charity. Dr Simon Newman, the charity's chief scientific officer, said: "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients ensuring rapid access to the optimal standard of care and - crucially - removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis." Queen Elizabeth Hospital Birmingham, and Great Ormond Street Children's Hospital and Kings College Hospital in London, are among those now setting up their own testing of the method alongside their existing processes. Follow BBC Nottingham onFacebook, onX, or onInstagram. Send your story ideas toeastmidsnews@bbc.co.ukor viaWhatsAppon 0808 100 2210.
New brain tumour test a 'game changer', say experts
TruthLens AI Suggested Headline:
"New Genetic Testing Method Reduces Brain Tumour Diagnosis Time from Weeks to Hours"
Bbc News
7.3
TruthLens AI Summary
Researchers at the University of Nottingham, in collaboration with Nottingham University Hospitals NHS Trust, have developed a groundbreaking genetic testing method that significantly reduces the time needed to diagnose brain tumours from weeks to mere hours. This 'ultra-rapid' testing technique has already been applied in 50 surgical operations, achieving a remarkable 100% success rate in identifying the specific type of tumour. Traditionally, diagnosing brain tumours involves extracting samples during surgery, which are then sent for analysis in a pathology lab—a process that can take up to eight weeks. Such delays can lead to complications in treatment, as surgeons may discover the need for more aggressive interventions only after the initial diagnosis is received. The new method promises to deliver results in as little as 90 minutes, allowing surgeons to make real-time decisions regarding the necessity of further surgical intervention during the patient's original operation, thus potentially sparing them from additional surgeries and reducing overall patient anxiety associated with prolonged waiting times for results.
The innovative approach utilizes nanopore genetic sequencing and specialized software named ROBIN, enabling scientists to focus on specific DNA segments for quicker analysis. The implications of this rapid diagnosis are profound. Patients can receive timely treatment options, such as radiation or chemotherapy, without the extended waiting period that often complicates their conditions. Patient testimonials underscore the emotional relief this advancement brings; for instance, families like that of two-year-old Nancy, who underwent multiple surgeries and chemotherapy, express that such rapid testing could have alleviated significant anxiety during critical treatment phases. The potential impact of this new testing method extends beyond individual cases, as it stands to revolutionize the standard of care for brain tumour patients across the UK, with other hospitals, including Queen Elizabeth Hospital Birmingham and Great Ormond Street Children's Hospital, beginning to implement similar testing protocols. Experts emphasize that this swift diagnosis not only enhances treatment efficacy but also fundamentally changes the patient experience by reducing uncertainty during a challenging time.
TruthLens AI Analysis
The recent development of an ultra-rapid brain tumour test marks a significant advancement in medical diagnostics. This new method not only shortens the diagnosis time from weeks to mere hours but also promises to enhance patient care and treatment outcomes. By leveraging genetic testing, the collaboration between the University of Nottingham and Nottingham University Hospitals NHS Trust has produced a reliable tool that has already demonstrated a 100% success rate in identifying tumor types in clinical settings.
Implications for Patient Care
The article emphasizes the potential benefits for patients who previously faced prolonged waiting periods for diagnoses. Surgeons highlighted that the timely identification of tumor types could lead to more effective treatment strategies, possibly preventing the need for additional surgeries. This is particularly significant given the diverse nature of brain tumours, with over 100 known types requiring precise identification to tailor treatment plans accordingly.
Public Perception and Trust
Experts described the new testing method as a "game changer," which likely aims to generate excitement and optimism within the medical community and among patients. By framing the development in a positive light, the article seeks to foster trust in medical advancements and the NHS's capabilities. However, there is a subtle pressure on other NHS institutions to adopt similar tests, which could lead to increased expectations from patients regarding diagnostic efficiency.
Potential Concealment of Issues
While the article is largely positive, it may sidestep potential challenges such as the implementation logistics of the new testing method across various hospitals or the costs associated with adopting this technology. These aspects are crucial for understanding the broader implications of such innovations and their feasibility within the current healthcare system.
Manipulation and Reliability
The article’s tone and language suggest a strong promotional angle, which raises questions about its objectivity. By emphasizing the success rate and the transformative potential of the technology, there is a risk of presenting an overly optimistic view that may not fully account for the complexities involved in broader implementation. This could indicate a manipulative aspect in how the information is presented, potentially downplaying challenges that lie ahead.
Comparison to Other Innovations
In relation to other medical advancements, this testing method aligns with a growing trend of rapid and precise diagnostics in healthcare. It reflects a broader movement towards personalized medicine, where treatments are tailored to individual patient needs. Such innovations often attract significant media attention and investment, potentially influencing market dynamics and healthcare priorities.
Economic and Societal Impact
The introduction of this testing method could have far-reaching implications for healthcare economics, potentially reducing costs associated with prolonged treatment timelines and unnecessary surgeries. This may affect hospital budgets and resource allocation, ultimately shaping how healthcare services are delivered.
Community Engagement
The news is likely to resonate more with communities affected by brain tumours, including patients, families, and advocacy groups. It aims to foster a sense of hope and urgency for better treatment options, which can mobilize support for further research and funding in this area.
Market Reactions
In terms of market impact, advancements in medical testing can influence stock prices of companies involved in healthcare technology and diagnostics. Investors often react positively to news of breakthroughs that promise to enhance treatment efficacy and efficiency, potentially affecting stocks of related entities.
Global Context
While this news is localized to the UK, it reflects global trends in healthcare innovation. The emphasis on rapid diagnostics aligns with ongoing discussions about improving healthcare systems worldwide, making it relevant to broader health policy dialogues.
Use of AI in Reporting
It is possible that AI tools were employed in drafting this article to streamline information and ensure clarity in presenting complex medical advancements. The choice of language and structure could indicate an influence of AI in making the content more accessible and engaging for a general audience.
In conclusion, while the article presents a hopeful narrative about a new medical test, it is essential to consider the broader context, including potential challenges and the need for balanced reporting. The reliability of the information seems high given the success rates mentioned, but the presentation might carry an undertone of promotional intent that warrants a critical lens.